TrialHaematologica2021

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.

Paula Cramer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.